X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biopharmadive.com/news/roche-impairment-write-down-spark-gene-therapy/641939/
https://www.newswire.ca/news-releases/novartis-and-the-pan-canadian-pharmaceutical-alliance-pcpa-conclude-negotiations-for-luxturna-r-a-gene-therapy-for-previously-untreatable-inherited-vision-loss-1--803517945.html
https://www.fiercebiotech.com/research/vivo-gene-editing-grabs-spotlight-after-intellia-triumph-but-challenges-loom
https://www.fiercebiotech.com/biotech/luxturna-inventor-behind-new-eye-gene-therapy-biotech-opus-genetics-snags-19m
https://endpts.com/2-am-on-a-mission-to-treat-patients-not-covered-by-luxturna-horama-refuels-with-a-series-b-expansion-and-a-new-name/
http://www.pharmatimes.com/news/first_patient_undergoes_luxturna_gene_therapy_on_nhs_1326391
https://www.statnews.com/2019/12/18/manufacturing-the-next-breakthrough-in-gene-therapy/
https://www.contractpharma.com/contents/view_breaking-news/2019-10-23/aldevron-nature-technology-team-up-for-gene-therapy-manufacturing/
https://www.biopharmadive.com/news/proqr-eye-disease-gene-medicine-trial-readout-sepofarsen/564752/
https://www.fiercepharma.com/pharma/cigna-gives-gene-therapies-novartis-and-spark-a-boost-comprehensive-payment-plan
https://www.biospace.com/article/roche-spark-push-back-stock-offer-deadline-as-ftc-reviews-continue/?s=79
https://www.reuters.com/article/us-novartis-britain/uk-cost-watchdog-recommends-novartis-blindness-therapy-luxturna-idUSKCN1VO2U9?feedType=RSS&feedName=healthNews
https://www.biospace.com/article/despite-drug-pricing-concerns-poll-shows-americans-tolerate-high-costs-of-one-time-gene-therapies/
https://www.fiercepharma.com/pharma/most-expensive-meds-u-s-topped-by-novartis-and-spark-gene-therapies
https://www.biospace.com/article/roche-s-acquisition-of-spark-hits-another-regulatory-snag-in-the-u-s-and-u-k-/?s=79
https://www.fiercepharma.com/pharma/roche-pushes-back-spark-offer-a-third-time-will-it-close-deal-time-or-ever
https://www.raps.org/news-and-articles/news-articles/2019/4/two-gene-therapy-approvals-headline-cbers-fy-2018
http://www.evaluate.com/vantage/articles/news/deals/johnson-johnson-dips-toe-gene-therapy?mkt_tok=eyJpIjoiTW1Jd1pqZ3lNV1JsWlRjMyIsInQiOiJZUEhaV3JnZktHSXNRdTBFYnAxNFN4NWkrelo3RmZ3eFRWZE5oZVVwOEVUWHJvZktuME1FNERjVTZqNERndTNkY2RqdFlEQ3hERE5tQTFqNXBRY2dBenp1QjVaTktlMUpQQ3lEUHdrd1N2UE1mT3hQWTNacTNSTFpsTlBQTldzYyJ9
https://www.ema.europa.eu/documents/overview/luxturna-epar-medicine-overview_en.pdf
https://www.biopharmadive.com/news/spark-gene-therapy-manufacturing-scale-cmc/545723/
https://endpts.com/what-do-martin-shkreli-gilead-and-takeda-have-in-common-they-all-figure-prominently-in-the-new-top-20-list-of-the-worlds-most-expensive-drugs/
https://uk.reuters.com/article/novartis-luxturna/novartis-gets-european-approval-for-sight-therapy-luxturna-idUKFWN1XX0G1?rpc=401&
https://uk.reuters.com/article/us-novartis-luxturna/novartis-gets-european-approval-for-sight-therapy-luxturna-idUKKCN1NS0FM
https://endpts.com/longtime-apitope-ceo-keith-martin-steps-down-clearside-biomedical-taps-spark-exec-as-cmo/
http://www.pharmatimes.com/news/chmp_puts_13_therapies_forward_for_eu_approval_1253165
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003025.jsp&mid=WC0b01ac058004d5c1
https://www.raps.org/news-and-articles/news-articles/2018/9/chmp-backs-13-new-medicines-maintains-negative-op?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2021%20September
https://www.ema.europa.eu/en/news/new-gene-therapy-rare-inherited-disorder-causing-vision-loss-recommended-approval
Market Place
Share 
